Search

Calmare NJ USA

Tag

Calmare clinical trial

CLINICAL TRIAL: Arachnoiditis Nerve Pain Relief

April 12, 2019

2019 CLINICAL TRIAL – DIAGNOSED ARACHNOIDITIS PATIENTS

Study

Calmare Therapy NJ USA (Scrambler Therapy) to Treat Diagnosed Cases of Arachnoiditis to Reduce Chronic Neuropathic Pain Symptoms

Phase

Pilot

What is Arachnoiditis?

Arachnoiditis is a chronic pain disorder caused by the inflammation of the arachnoid membrane and subarachnoid space that surround the nerves of the spinal cord. The inflammation can cause the meninges to adhere to the spinal cord and nerve roots.

Because the nerve roots are affected, symptoms such as numbness, tingling, and burning pain are often felt in the lower back or legs.

Severe cases of arachnoiditis can result in the loss of motor function, loss of bladder and bowel control and even paralysis.

Arachnoiditis can arise from infection, direct spinal injury, and chronic compression of the spinal nerves or invasive spinal surgeries.

Study Conducted by

Dr. Michael J. Cooney
Calmare Therapy NJ USA

Location

Rutherford, NJ (10 miles from New York City)

Study Start Date

May 13 – 24, 2019

Details

Calmare Therapy NJ USA is one of only seven Calmare Certified providers of scrambler therapy, an FDA-cleared, non-invasive, pain-free, drug-free technology to treat patients suffering from several types of long-term, high-intensity pain.

Scope of May 2019 Calmare Study

We are conducting a free, 10-treatment (one 35-minute daily therapy session) clinical trial study for pre-qualified patients suffering from diagnosed Arachnoiditis to determine the efficacy of scrambler therapy as a viable treatment solution for condition-induced neuropathy.

Eligibility Criteria

Pre-approved study patients must be available to undergo a protocol of 10 treatments once per day. There is no charge for the series of 10 treatments.

Travel, daily transportation, meals and accommodations are not covered for this trial

Informed Consent

People who agree to take part in the study are asked to sign an Informed Consent Form. However, signing the form does not mean approved trial participants must stay in the study for the duration. Volunteer participants can leave the study at any time—either before the study starts or at any time during the study or the follow-up period.

The informed consent process continues throughout the study. If new benefits, risks, or side effects are discovered during the study, clinical trial researchers will; inform the participants.

To Apply  |  Contact Us  |  For More Information

To find out more and determine if you qualify for the no-cost study, please contact for a phone consultation or email us at info@calmaretherapynj.com

Dr. Michael Cooney
Clinical Director
Calmare Therapy NJ USA
(201) 933.4440 | calmaretherapynj.com

 

Featured post

ADDED DATES: Fibromyalgia Clinical Trial at Calmare NJ USA

May 3, 2018

CLINICAL TRIAL – DIAGNOSED FIBROMYALGIA

Study 

To Measure Chronic Pain Reduction in Patients Diagnosed with Treatment-Resistant Fibromyalgia after Administering 3-5 Calmare (Scrambler Therapy) Treatments

Phase

Pilot

What is Fibromyalgia?

Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. Researchers believe that fibromyalgia amplifies painful sensations by affecting the way your brain processes pain signals.

Calmare scrambler therapy is a drug-free, non-invasive, FDA-cleared therapy that painlessly scrambles a misfiring pain message from the brain, suggesting there is pain, when, in fact, there is not.

Purpose of the Clinical Trial

To document the viability of using scrambler therapy as a pain management solution to significantly reduce or eliminate neuropathic pain in patients diagnosed with Fibromyalgia.

Study Conducted by

Michael J. Cooney, D.C., Clinical Director

Rutherford Allied Medical Group  | Calmare Therapy NJ USA

 Location

323 Union Ave., Rutherford, New Jersey (10 miles from New York City)

Trial Start Date (Rolling Admission)

May 21, 2018 to August 31, 2018

Testing Period

After a personal consultation and evaluation by Dr. Michael Cooney, selected trial candidates will undergo 3 to 5 treatments, once daily, lasting approximately 35 minutes. Additional treatments will be at the discretion of the clinical director.

Calmare Therapy NJ Background

Calmare Therapy NJ / Rutherford Allied Medical Group, is one of only eight certified providers of Calmare Pain Therapy Treatment®, an FDA-cleared, non-invasive, pain-free, drug-free technology to treat patients suffering from several types of long-term, high-intensity pain.

Scope of the Calmare Fibromyalgia Clinical Trial

We are conducting a no-cost, 3 or more treatments (one 35-minute daily therapy session) clinical trial study for pre-qualified patients suffering from diagnosed fibromyalgia FMS to determine the efficacy of scrambler therapy as a viable treatment solution for condition-induced neuropathy.

Trial participants are selected at the discretion of Dr. Michael Cooney, clinical director, Calmare Therapy NJ USA | Application Form

Eligibility Criteria

Selected clinical trial volunteers must be available to undergo the protocol once per day. We will make every effort to schedule daily appointments at a convenient time for participants.

Travel, daily transportation, meals and accommodations are at the trial participant’s expense.

Contraindications

We are seeking trial candidates with few or no additional medical conditions, in order to maximize the treatment and outcome of the FMS condition exclusively.

Candidates are not eligible for the trial if they have the following medical conditions, devices or prescribed medications:

  • Pacemaker
  • Automatic implantable cardioverter-defibrillator (AICD)
  • Pregnancy
  • Epilepsy
  • Heart conditions
  • Anticonvulsants
  • Antidepressants

Informed Consent

Clinical trial volunteers who are selected for the study are asked to sign the Informed Consent Form. Signing this document does not require participants to remain for the duration of the study, however.

People can leave the study at any time—either before the study starts or at any time during the study or the follow-up period. The informed consent process continues throughout the study. If new benefits, risks, or side effects are discovered during the study, the researchers must inform the participants.

Publicity

Calmare Therapy NJ reserves the right to publish data about any participant’s trial outcome. We will not include your name or image, at your request.

To Apply / Contact Us / For More Information

There is no fee to participate. 

To apply for the trial, click here to complete and scan the attached application form and return it to calmarenj@gmail.com or fax to (201) 933-8159.

For questions about the trial, please contact:

Dr. Michael Cooney

Clinical Director

Calmare Therapy NJ / Rutherford Allied Medical Group

(201) 933.4440   |   calmarenj@gmail.com

 

 

 

Calmare Therapy Clinical Trial: Diagnosed Diabetic Nerve Pain

Calmare Therapy (Scrambler Therapy) to Treat Diagnosed Cases of Diabetic Nerve Pain and Reduce Chronic Neuropathic Pain Symptoms

clinical trial

Phase  

Pilot

What is Diabetic Neuropathy?

Diabetic neuropathy is a type of nerve damage that can occur as a side effect from diagnosed diabetes. High blood sugar (glucose) can damage nerve fibers throughout your body, but diabetic neuropathy–nerve pain as a result of the disease of diabetes–most often damages nerves in the lower extremities (legs and feet) and the hands.

Depending on the affected nerves, symptoms of diabetic neuropathy can range from pain and numbness in the extremities to digestive, urinary tract, blood vessels and heart complications. For some people, these symptoms are mild; for others, diabetic neuropathy can be extremely painful, debilitating and disabling.

Even with stringent blood sugar control and a healthy lifestyle, some diabetic patients still experienced severe diabetic nerve pain.

Study Conducted by

Michael J. Cooney, D.C., Clinical Director

Rutherford Allied Medical Group / Calmare Therapy NJ

Location

323 Union Ave., Rutherford, New Jersey (10 miles from New York City)

Study Start Date

Monday, December 5 to Friday, December 16, 2016

Calmare Therapy NJ Background

Calmare Therapy NJ / Rutherford Allied Medical Group, is one of only ten certified providers of Calmare Pain Therapy Treatment®, an FDA-cleared, non-invasive, pain-free, drug-free technology to treat patients suffering from several types of long-term, high-intensity pain.

Since introducing the treatment in 2011, Dr. Cooney has successfully treated more than 500 patients with severe neuropathic pain as a result of injury, surgery or disease.

Scope of the Diabetic Nerve Pain Study

We are conducting a no-cost, 10-treatment (one 35-minute daily therapy session) Calmare Therapy clinical trial study for pre-qualified patients suffering from diagnosed diabetic neuropathy to determine the efficacy of scrambler therapy as a viable treatment solution for condition-induced neuropathy.

Eligibility Criteria

Selected clinical trial volunteers must be available to undergo a protocol of 10 treatments, once per day, Monday through Friday. We will make every effort to schedule daily appointments at a convenient time for participants.

Travel, daily transportation, meals and accommodations are at the trial participant’s expense

Informed Consent

Clinical trial volunteers who are selected for the study are asked to sign the Informed Consent Form. Signing this document does not require participants to remain for the duration of the study, however.

People can leave the study at any time—either before the study starts or at any time during the study or the follow-up period. The informed consent process continues throughout the study. If new benefits, risks, or side effects are discovered during the study, the researchers must inform the participants.

Publicity

Calmare Therapy NJ reserves the right to publish data about any participant’s trial outcome. We will not include your name or image, at your request.

To Apply / Contact Us / For More Information

To apply for the trial, learn more or ask questions, please contact:

Dr. Michael Cooney

Clinical Director

Calmare Therapy NJ / Rutherford Allied Medical Group

(201) 933.4440   |   calmarenj@gmail.com

Medscape reports on another positive clinical trial using Calmare for cancer pain

medscapeAnother Calmare Therapy clinical trial, conducted with people battling neuropathic pain as a result of chemotherapy treatment, has again shown  positive patient outcomes (significant lessening of pain) according to a new report published this week by Medscape, an affiliate of WebMD. (You have to register to read the article, but the process is free, quick and easy).

clinical trialCalmare Trial Key Points / Excerpts:

  • Scrambler therapy was not originally developed for the treatment of cancer-related neuropathic pain. Rather, it was developed for chronic pain and, indeed, has been used in many patients with noncancer-related pain, including low back pain.
  • Regardless of the type of neuropathic pain being treated, scores on the 11-point Numerical Rating Scale (NRS) decreased significantly from baseline to 1-month follow-up (P < .001).
  • The need for ‘rescue opioids’ dropped from a baseline dose of 5 mg to 0 mg at the end of the study.
  • No adverse side effects (“events”) that could have been associated with the therapy were reported.
  • A research team from the Massey Cancer Center at Virginia Commonwealth University in Richmond reported similar findings using the same cutaneous electro-stimulation device (scrambler therapy) for CIPN (J Pain Symptom Manage. 2010;40:883-891).
  • Some patients relapsed, but re-treatment and maintenance therapy (booster treatments) provided relief and, again, no adverse effects from treatment were observed.
  • Charles Loprinzi, MD, PhD, from the Mayo Clinic in Rochester, Minnesota, and colleagues conducted a trial with 37 CIPN patients and achieved similar study outcomes (Support Care Cancer. 2015 23:943-951).
  • Dr. Loprinzi stated that people have been slow to explore scrambler therapy use because “it sounds too good to be true…” He also reported to Medscape that efforts to conduct larger trials are ongoing, but it takes time and money to perform these trials.

The European Journal of Oncology Nursing also published an abstract of the study reported by Medscape.


Blog at WordPress.com.

Up ↑

%d bloggers like this: